ICER Will Assess Value and Effectiveness of Multiple Sclerosis Treatments

The Institute for Clinical and Economic Review (ICER) will perform value and effectiveness assessments on several drugs for multiple sclerosis. The drugs include several monoclonal antibody treatments from manufacturers like Biogen, Novartis, and Genentech and some biosimilars for Rituximab. The assessment will also cover oral therapies, including dimethyl fumarate (Tecfidera), monomethyl fumarate (Vumerity), and more. The results of the assessment will be discussed in January 2023 at a meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC).

According to ICER, “ All interested stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. Comments can be submitted by email to publiccomments@icer.org and must be received by 5 PM ET on May 12, 2022.”

To read more and submit your comments, click here.

(Source: ICER, April 21^st, 2022)